## Medix Biochemica

Dear Valued Customer,

Since the acquisition of ViroStat LLC by Medix Biochemica, we have been focusing on the full integration of this company to improve our customer experience.

As was previously communicated on May 9, 2024, effective October 1, 2024, and as part of this integration process, we will be enhancing the order processes for the ViroStat product range.

This change applies to all ViroStat antibody and antigen products.

### What will be changing on October 1, 2024?

Ordering processes will be migrated to the Medix Biochemica ERP system and the ViroStat product portfolio will be sold through Medix Biochemica USA Inc. for our US, Canadian and South American customers, or through Oy Medix Biochemica Ab, Finland for our European and Rest of the World customers.

# As from October 1, 2024, all orders for ViroStat products must be placed to Medix Biochemica: <a href="mailto:orders@medixbiochemica.com">orders@medixbiochemica.com</a>.

You may need to implement a new vendor registration process as part of this change. Our team will be available to support you with this.

### It is important to note that there will be <u>no changes</u> to:

- The form, fit, or function of any products
- The manufacturing entity, location, processes, or team members that build and ensure the quality of our products,
- The products will remain under ViroStat's quality management systems and will <u>not be sold</u> under Medix Biochemica's ISO13485 certification.

Our primary objective remains the continuity of providing quality products, service, and delivery that you have relied on for years.

### Until October 1, 2024, please continue to use current ViroStat order and remittance processes.

Additional information and support, including vendor invoicing details and W9 from can be found by following this link: Important Updates on ViroStat Integration | Medix Biochemica

Should you have any questions, please contact your Medix Biochemica sales representative or call a member of our Customer Service Department on either +358 9 547680 (Finland) / 1-314-968-1091 (US). Alternatively, we can be reached by email at: medix@medixbiochemica.com

As always, we thank you for your continued loyalty, and we look forward to continued interactions with you, our valued customers.

Sincerely,

Kevin Doss

Quality & Regulatory Affairs Director Medix Biochemica

